Cleveland BioLabs, Inc

(NASDAQ:CBLI)

Latest On Cleveland BioLabs, Inc (CBLI):

Date/Time Type Description Signal Details
2021-09-01 01:03 ESTNewsCytocom to rename as Statera BioPharmaN/A
2021-08-16 15:09 ESTNewsCleveland BioLabs reports Q2 resultsN/A
2021-08-16 15:08 ESTNewsCytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-29 15:37 ESTNewsCytocom secures $90M in debt and equity financingN/A
2021-07-20 23:41 ESTNewsCleveland Bio pops 4% after SEC declared effectiveness of registration statementN/A
2021-02-20 00:37 ESTNewsCleveland BioLabs readies $14M stock offeringN/A
2021-02-18 12:13 ESTNewsCleveland Bio files Form S-4 for Cytocom merger, shares up 27%N/A
2021-02-17 00:58 ESTNewsICON partners with Cytocom in a Phase 3 trial for Crohn's diseaseN/A
2020-12-13 03:27 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 19:22 ESTFinancialsCompany financials have been released.Neutral
2020-11-15 11:32 ESTFinancialsCompany financials have been released.Neutral
2020-11-01 17:27 ESTFinancialsCompany financials have been released.Neutral
2020-10-20 17:14 ESTNewsCleveland BioLabs up 66% on planned merger with CytocomN/A
2020-09-24 00:23 ESTFinancialsCompany financials have been released.Neutral
2020-09-19 08:27 ESTFinancialsCompany financials have been released.Neutral
2020-08-16 12:19 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 00:27 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:31 ESTFinancialsCompany financials have been released.Neutral
2020-07-10 08:21 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 08:17 ESTFinancialsCompany financials have been released.Neutral
2020-06-27 14:49 ESTNewsCleveland BioLabs joins COVID vaccine-stoked rallyN/A
2020-06-01 20:56 ESTNewsCleveland Biolabs -11.7% on $3.175M registered direct offeringN/A
2020-05-31 16:49 ESTFinancialsCompany financials have been released.Neutral
2020-05-23 01:09 ESTNewsCleveland BioLabs files for $50M mixed shelfN/A
2020-05-20 12:27 ESTFinancialsCompany financials have been released.Neutral
2020-05-16 20:41 ESTNewsCleveland BioLabs reports Q1 resultsN/A
2020-05-03 08:24 ESTFinancialsCompany financials have been released.Neutral
2020-04-18 00:18 ESTFinancialsCompany financials have been released.Neutral
2020-04-11 06:48 ESTNewsCoronavirus death toll jumps in ChinaN/A
2020-04-11 06:34 ESTNewsCoronavirus plays - vaccines, drugs & infection control productsN/A
2020-04-11 06:26 ESTNewsFamiliar names gain as COVID-19 weighs on marketN/A
2020-04-11 04:16 ESTStock SplitA stock split has occured on Jan 28, 2015 with a split factor of 1:20.Neutral
2020-04-09 12:19 ESTFinancialsCompany financials have been released.Neutral
2020-04-07 00:27 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 23:20 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 03:22 ESTFinancialsCompany financials have been released.Neutral
2020-02-21 23:16 ESTFinancialsCompany financials have been released.Neutral
2020-02-06 23:18 ESTFinancialsCompany financials have been released.Neutral
2020-01-29 23:19 ESTFinancialsCompany financials have been released.Neutral
2020-01-27 23:16 ESTFinancialsCompany financials have been released.Neutral
2020-01-15 23:17 ESTFinancialsCompany financials have been released.Neutral
2019-12-16 23:18 ESTFinancialsCompany financials have been released.Neutral
2019-11-27 23:17 ESTFinancialsCompany financials have been released.Neutral
2019-11-26 23:17 ESTFinancialsCompany financials have been released.Neutral
2019-11-22 23:15 ESTFinancialsCompany financials have been released.Neutral
2019-11-18 23:12 ESTFinancialsCompany financials have been released.Neutral
2019-11-15 23:16 ESTFinancialsCompany financials have been released.Neutral
2019-11-14 16:55 ESTNewsCleveland BioLabs reports Q3 resultsN/A
2019-11-12 09:11 ESTNewsCleveland BioLabs: Another Year - Only Cash Burn To ShowN/A
2019-11-06 23:16 ESTFinancialsCompany financials have been released.Neutral

About Cleveland BioLabs, Inc (CBLI):

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.

CBLI Quotes by TradingView

See Advanced Chart

General

  • Name Cleveland BioLabs, Inc
  • Symbol CBLI
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 7
  • Last Split Factor1:20
  • Last Split Date2015-01-28
  • Fiscal Year EndDecember
  • IPO Date2006-07-21
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.cbiolabs.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 109.07
  • Enterprise Value Revenue 136.1
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Operating Margin -331%
  • Return on Assets -48%
  • Return on Equity -110%
  • Revenue 631842
  • Earnings Per Share -$0.27
  • Revenue Per Share $0.05
  • Gross Profit -543006
  • Quarterly Earnings Growth -83.8%
View More

Highlights

  • Market Capitalization 99.48 million
  • EBITDA -3441400
  • PE Ratio -18.6
  • Analyst Target Price $2
  • Book Value Per Share -$0.26
View More

Share Statistics

  • Shares Outstanding 15.38 million
  • Shares Float 6.59 million
  • % Held by Insiders 5641%
  • % Held by Institutions 6.67%
  • Shares Short 18008
  • Shares Short Prior Month 53219
  • Short Ratio 0.03
View More

Technicals

  • Beta 0.59
  • 52 Week High $9.53
  • 52 Week Low $1.27
  • 50 Day Moving Average 6.21
  • 200 Day Moving Average 3.68
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cleveland BioLabs, Inc (CBLI) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cleveland BioLabs, Inc (CBLI) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-17$N/A-$0.06
2020-06-302020-09-30$N/A-$0.06
2020-03-312020-06-30$156042-$0.03
2019-12-312020-03-31$368900-$0.05
2019-09-302019-12-31$269635-$0.06
2019-06-302019-09-30$276967-$0.04
2019-03-312019-06-30$197919-$0.05
2018-12-312019-03-31$235713-$0.08
2018-09-302018-12-31$283307-$0.04
2018-06-302018-09-30$391591-$0.10
2018-03-312018-06-30$227576-$0.08
2017-12-312018-03-31$870000-$0.11
2017-09-302017-12-31$297000-$0.10
2017-06-302017-09-30$206000-$0.11
2017-03-312017-06-30$575000-$0.50
2016-12-312017-03-31$989000-$0.15
2016-09-302016-12-31$1.14 million-$0.11
2016-06-302016-09-30$575000$0.10
2016-03-312016-06-30$813000-$0.17
2015-12-312016-03-31$1.27 million-$0.06
2015-09-302015-12-31$502000-$0.13
2015-06-302015-09-30$330000-$0.31
2015-03-312015-06-30$607000-$1.12
2014-12-312015-03-31$1.39 million-$1.14
2014-09-302014-12-31$415000$3.95
2014-06-302014-09-30$562000-$1.43
2014-03-312014-06-30$1.33 million-$1.53-$1.00-52.67%
2013-12-312014-03-31$3.87 million-$0.63-$2.4073.56%
2013-09-302013-12-31$1.64 million-$0.16-$2.7094.01%
2013-06-302013-09-30$1.61 million-$1.82-$3.1041.43%
2013-03-312013-06-30$1.37 million-$1.35-$3.4060.19%
2012-12-312013-03-31$2.16 million-$4.36-$4.20-3.73%
2012-09-302012-12-31$219000$1.46
2012-06-302012-09-30$259000-$6.06-$0.80-657.95%
2012-03-312012-06-30$931000-$2.84-$2.902.01%
2011-12-312012-03-31$1.95 million-$3.02-$2.60-16.22%
2011-09-302011-12-31$3.8 million-$4.12-$2.80-47.05%
2011-06-302011-09-30$569000-$1.60-$2.6038.46%
2011-03-312011-06-30$2.47 million$6.00-$0.203100%
2010-12-312011-03-31$3.76 million-$3.78-$1.60-136.13%
2010-09-302010-12-31$3.19 million-$9.73-$2.20-342.1%
2010-06-302010-08-16$4.21 million-$1.80-$1.800%
2010-03-312010-05-14$4.17 million-$2.80-$2.20-27.27%
2009-12-312010-03-22$4.63 million$1.20-$1.60175%
2009-09-302009-11-12$3.22 million-$6.60-$1.80-266.67%
2009-06-302009-08-13$4.19 million-$9.06
2009-03-312009-05-13$2.31 million-$4.74
2008-12-312009-03-30$1.5 million-$5.40-$4.20-28.57%
2008-09-302008-11-14$1.85 million-$4.60-$4.600%
2008-06-302008-08-12$675000-$6.00-$4.60-30.43%
2008-03-312008-05-14$676000-$6.60-$17.6062.5%
2007-12-312008-03-21$401000-$15.40-$8.80-75%
2007-09-302007-11-14$661000-$10.80-$6.20-74.19%
2007-06-302007-08-14$636000-$12.80-$5.20-146.15%
2007-03-312007-05-15$321000-$7.00-$4.40-59.09%
2006-12-312007-03-29$231000-$6.97
2006-09-302006-11-13$324000-$3.01
2006-06-302006-08-25$575000-$4.21

Cleveland BioLabs, Inc (CBLI) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Cleveland BioLabs, Inc (CBLI) Chart:

CBLI chart by TradingView

Cleveland BioLabs, Inc (CBLI) News:

Below you will find a list of latest news for Cleveland BioLabs, Inc (CBLI) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cleveland BioLabs, Inc (CBLI) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Cleveland BioLabs, Inc (CBLI) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000091957420004035/0000919574-20-004035-index.htm
2016-02-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1318641/000000000016065068/0000000000-16-065068-index.htm
2020-05-28UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1318641/000000000020004708/0000000000-20-004708-index.htm
2020-06-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000091957420004035/0000919574-20-004035-index.htm
2020-01-24SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000094078020000005/0000940780-20-000005-index.htm
2016-01-29S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1318641/000121390016010481/0001213900-16-010481-index.htm
2016-02-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016010580/0001213900-16-010580-index.htm
2016-03-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1318641/000121390016011315/0001213900-16-011315-index.htm
2016-03-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1318641/000121390016011630/0001213900-16-011630-index.htm
2016-03-21424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1318641/000121390016011763/0001213900-16-011763-index.htm
2016-05-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016013209/0001213900-16-013209-index.htm
2016-05-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016013586/0001213900-16-013586-index.htm
2016-07-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016015364/0001213900-16-015364-index.htm
2016-07-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016015366/0001213900-16-015366-index.htm
2016-07-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390016015368/0001213900-16-015368-index.htm
2018-02-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000121390018002383/0001213900-18-002383-index.htm
2018-08-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000121390018011138/0001213900-18-011138-index.htm
2016-02-18PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000004/0001318641-16-000004-index.htm
2016-02-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000006/0001318641-16-000006-index.htm
2016-02-2310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000131864116000009/0001318641-16-000009-index.htm
2016-03-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000012/0001318641-16-000012-index.htm
2016-03-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000014/0001318641-16-000014-index.htm
2016-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000016/0001318641-16-000016-index.htm
2016-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000018/0001318641-16-000018-index.htm
2016-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000020/0001318641-16-000020-index.htm
2016-05-1610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864116000023/0001318641-16-000023-index.htm
2016-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000029/0001318641-16-000029-index.htm
2016-07-218-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000031/0001318641-16-000031-index.htm
2016-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000034/0001318641-16-000034-index.htm
2016-07-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000036/0001318641-16-000036-index.htm
2016-08-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000040/0001318641-16-000040-index.htm
2016-08-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864116000041/0001318641-16-000041-index.htm
2016-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000043/0001318641-16-000043-index.htm
2016-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864116000046/0001318641-16-000046-index.htm
2016-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864116000047/0001318641-16-000047-index.htm
2017-02-21PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000007/0001318641-17-000007-index.htm
2017-02-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000010/0001318641-17-000010-index.htm
2017-02-2210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000131864117000012/0001318641-17-000012-index.htm
2017-03-03DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000016/0001318641-17-000016-index.htm
2017-03-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000018/0001318641-17-000018-index.htm
2017-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000020/0001318641-17-000020-index.htm
2017-04-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000024/0001318641-17-000024-index.htm
2017-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000027/0001318641-17-000027-index.htm
2017-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864117000028/0001318641-17-000028-index.htm
2017-06-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000031/0001318641-17-000031-index.htm
2017-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864117000037/0001318641-17-000037-index.htm
2017-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000039/0001318641-17-000039-index.htm
2017-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864117000043/0001318641-17-000043-index.htm
2017-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864117000045/0001318641-17-000045-index.htm
2018-03-0610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000131864118000005/0001318641-18-000005-index.htm
2018-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000007/0001318641-18-000007-index.htm
2018-03-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000010/0001318641-18-000010-index.htm
2018-03-12DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000011/0001318641-18-000011-index.htm
2018-03-21424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1318641/000131864118000013/0001318641-18-000013-index.htm
2018-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000015/0001318641-18-000015-index.htm
2018-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000017/0001318641-18-000017-index.htm
2018-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000021/0001318641-18-000021-index.htm
2018-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864118000023/0001318641-18-000023-index.htm
2018-06-19S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000025/0001318641-18-000025-index.htm
2018-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000027/0001318641-18-000027-index.htm
2018-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000029/0001318641-18-000029-index.htm
2018-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000036/0001318641-18-000036-index.htm
2018-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864118000037/0001318641-18-000037-index.htm
2018-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000038/0001318641-18-000038-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864118000042/0001318641-18-000042-index.htm
2018-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864118000043/0001318641-18-000043-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000131864119000005/0001318641-19-000005-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000007/0001318641-19-000007-index.htm
2019-03-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000010/0001318641-19-000010-index.htm
2019-03-15DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000011/0001318641-19-000011-index.htm
2019-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000013/0001318641-19-000013-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000018/0001318641-19-000018-index.htm
2019-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864119000019/0001318641-19-000019-index.htm
2019-05-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000021/0001318641-19-000021-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000024/0001318641-19-000024-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000131864119000025/0001318641-19-000025-index.htm
2019-08-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000131864119000027/0001318641-19-000027-index.htm
2019-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774919020455/0001437749-19-020455-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774919022930/0001437749-19-022930-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000143774919022938/0001437749-19-022938-index.htm
2019-11-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774919023068/0001437749-19-023068-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774919023806/0001437749-19-023806-index.htm
2019-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774919024606/0001437749-19-024606-index.htm
2019-12-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000143774919024826/0001437749-19-024826-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920003393/0001437749-20-003393-index.htm
2020-03-31NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405https://www.sec.gov/Archives/edgar/data/1318641/000143774920006663/0001437749-20-006663-index.htm
2020-04-1510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000143774920007716/0001437749-20-007716-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1318641/000143774920008857/0001437749-20-008857-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920009193/0001437749-20-009193-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000143774920010885/0001437749-20-010885-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920010888/0001437749-20-010888-index.htm
2020-05-21S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1318641/000143774920011586/0001437749-20-011586-index.htm
2020-05-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1318641/000143774920011817/0001437749-20-011817-index.htm
2020-05-29424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1318641/000143774920012078/0001437749-20-012078-index.htm
2020-06-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1318641/000143774920012249/0001437749-20-012249-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920012341/0001437749-20-012341-index.htm
2020-06-04DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000143774920012488/0001437749-20-012488-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920016187/0001437749-20-016187-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1318641/000143774920017908/0001437749-20-017908-index.htm
2020-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920017915/0001437749-20-017915-index.htm
2020-08-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920018563/0001437749-20-018563-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021047/0001437749-20-021047-index.htm
2020-10-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021282/0001437749-20-021282-index.htm
2020-10-19425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021283/0001437749-20-021283-index.htm
2020-10-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021417/0001437749-20-021417-index.htm
2020-10-21425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021418/0001437749-20-021418-index.htm
2020-10-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021867/0001437749-20-021867-index.htm
2020-10-28425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1318641/000143774920021868/0001437749-20-021868-index.htm
2020-11-06DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1318641/000143774920023024/0001437749-20-023024-index.htm
2020-11-06DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1318641/000143774920023025/0001437749-20-023025-index.htm
2016-01-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000153561016000090/0001535610-16-000090-index.htm
2018-01-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1318641/000153561018000008/0001535610-18-000008-index.htm
2017-05-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1318641/000170467317000002/0001704673-17-000002-index.htm
2016-03-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1318641/999999999516003992/9999999995-16-003992-index.htm
2020-05-29EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1318641/999999999520001291/9999999995-20-001291-index.htm
2016-11-28CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1318641/999999999716027089/9999999997-16-027089-index.htm
2017-11-17CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1318641/999999999717009945/9999999997-17-009945-index.htm